Bangalore, 6th February 2024: Molbio Diagnostics, a leading player in point-of-care diagnostics, has launched ‘EDGE’- an innovative scaleup partnership program dedicated to accelerating game-changing healthcare technologies. As part of EDGE, Molbio Diagnostics will select high-potential MedTech startups and SMEs with groundbreaking solutions in rapid POC for high sensitivity immunodiagnostics and early cancer detection.
The main objective of this program is to help start-ups overcome critical hurdles in product development, translation and scaling up with the assistance of Molbio’s expertise, guidance and support. Participants will be able to leverage Molbio's extensive network and expertise to bring their innovation to a worldwide audience.
Over 12 weeks, selected participants will receive intensive mentorship, resources and expertise from Molbio's team of seasoned professionals. This culminates in the opportunity to forge co-development, manufacturing, or global sales partnerships with Molbio. At the end of the program, Molbio will engage with a few cohort participants for future partnerships which will involve bridge funding for product co-development, licensing, sales and distribution. The program will be conducted in hybrid mode and each cohort participant will receive bespoke guidance.
With the launch of EDGE,Molbio is set to reinforce its commitment to providing equitable & accessible healthcare by delivering solutions that truly matter.
To register for the program log on to https://partnership.
About Molbio Diagnostics:
Molbio Diagnostics is India’s first ‘unicorn’ in the medical technology sector that brings to healthcare professionals worldwide the Truelab® Real-Time Quantitative micro-PCR system comprising Truenat® technology that makes Real-Time PCR testing possible in all laboratories, in the field and near-patient settings. With a large and growing menu of Truenat® assays for infectious diseases, including TB, COVID-19, HIV, HCV, HBV, HPV, Influenza, etc., this rapid, portable technology enables early and accurate diagnosis and initiation of correct treatment right at the first point of contact.
So far, the platform is deployed in over 6,000 PHC/CHCs in India and over 1500 testing centers in over 70 countries around the world. Molbio currently has partnerships with SigTuple, ShanMukha Innovations, Niramai Health Analytix and a majority stake in Prognosys Medical Systems.
No comments:
Post a Comment